Antares Pharma, Inc. provided revenue guidance for the year 2022. For the year, the company expects revenue to be range of $200 to $220 million, which does not include any unapproved products and assumes no significant disruptions to supply or operations due to the ongoing COVID-19 pandemic. Excluding 2021 OTREXUP® proprietary revenue, the guidance range represents a 18% to 30% year-over-year growth rate.
Antares Pharma, Inc.
Equities
ATRS
US0366421065
Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | |
---|---|---|
-4.99% | 182B | |
+0.45% | 114B | |
-5.54% | 67.76B | |
+3.12% | 51.91B | |
+7.10% | 43.23B | |
+6.07% | 41.07B | |
+23.40% | 32.07B | |
+15.86% | 25B | |
-3.08% | 24.55B |